RHONE MA HOLDINGS |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.66 MYR | -.--% |
|
-1.49% | -4.35% |
| May. 15 | Rhone Ma's Profit Edges Up in Q1 | MT |
| May. 14 | Rhone Ma Holdings Berhad Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2024 * | 203M 43.15M | Sales 2025 * | 213M 45.23M | Capitalization | 146M 31.04M |
|---|---|---|---|---|---|
| Net income 2024 * | 12M 2.55M | Net income 2025 * | 12M 2.55M | EV / Sales 2024 * | 0.72 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.69 x |
| P/E ratio 2024 * |
12
x | P/E ratio 2025 * |
11.8
x | Employees | 205 |
| Yield 2024 * |
3.03% | Yield 2025 * |
3.33% | Free-Float | 15.49% |
More Fundamentals
* Assessed data
More news
| 1 week | -1.49% | ||
| 3 months | -1.49% | ||
| 6 months | -4.35% | ||
| Current year | -4.35% |
1 week
0.65
0.66
1 month
0.650.68
Current year
0.640.72
1 year
0.640.76
3 years
0.640.79
5 years
0.571.19
10 years
0.571.34
| Managers | Title | Age | Since |
|---|---|---|---|
Ban Keong Lim
CEO | Chief Executive Officer | 53 | 15-03-31 |
Yan San Chan
DFI | Director of Finance/CFO | 55 | 13-12-31 |
| Chief Operating Officer | 36 | 19-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 75 | 15-03-31 | |
Ban Keong Lim
CEO | Chief Executive Officer | 53 | 15-03-31 |
Kam Weng Foong
BRD | Director/Board Member | 64 | 15-03-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 0.66 | -.--% | 52,000 |
| 24-05-30 | 0.66 | -.--% | 49,600 |
| 24-05-29 | 0.66 | +0.76% | 5,000 |
| 24-05-27 | 0.655 | -2.24% | 9,000 |
| 24-05-24 | 0.67 | +2.29% | 252,200 |
End-of-day quote BURSA MALAYSIA, May 30, 2024
More quotes
Rhone Ma Holdings Berhad is a Malaysia-based investment holding company. The Company's subsidiaries are involved in the provision of end-to-end animal health solution and the distribution and supply of food ingredients. Its Animal health products and equipment segment includes marketing, trading, distribution and manufacturing of animal health products and equipment and undertaking research and development activities related to animal health, food safety and agriculture in animal health products. Its Food ingredients segment distributes and supplies food ingredients to manufacturers within the food and beverage industry. Its Others segment includes provision of diagnostic laboratory analyses and consultation services to the veterinary, agriculture and food industries, provision of tests and diagnostics services for human healthcare, conduct research and development in biotechnology and distribution of human healthcare and related products, management services and business of livestock.
Sector
Pharmaceuticals
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.66
MYR
Average target price
0.68
MYR
Spread / Average Target
+3.03%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -4.35% | 31.02M | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| -5.52% | 206B | |
| +6.17% | 164B | |
| -0.45% | 162B |
- Stock Market
- Equities
- RHONEMA Stock
